Skip to content
MarketHOT
中文
← Latest news

6-K - Vicore Pharma Holding AB (0002124403) (Filer)

SEC · EDGAR 财务披露 · November 5, 2026 at 5:15 PM ET



UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2026

(Commission File No. 001-43312)

Vicore Pharma Holding AB

(Translation of registrant’s name into English)

Kornhamnstorg 53

SE-111 27 Stockholm, Sweden

(Address of registrant’s principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒     Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐




Company Announcement and Interim Report

On November 5, 2026, Vicore Pharma Holding AB (the “Company”) announced its unaudited financial results for the third quarter ended September 30, 2026, which are further described in the Company’s Interim Report Q3 2026 and press release, copies of which are attached hereto as Exhibits 99.1 and 99.2, respectively, and are incorporated by reference herein.

Except as set forth below, the information in this Report on Form 6‑K, including Exhibit 99.1 hereto, shall be deemed to be incorporated by reference into the Company’s registration statement on Form S‑8 (File No. 333‑298501) and any related prospectus, as such registration statement and prospectus may be amended from time to time, and to be a part thereof from the date on which this report is furnished, to the extent not superseded by documents or reports subsequently filed or furnished.  

The information under the headings “CEO Comments” and “Sustainability at Vicore” in the attached Exhibit 99.1 and the information in the attached Exhibit 99.2 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. 

Exhibits

Description

99.1

Interim Report Q3 2026

99.2

Press release dated November 5, 2026

2


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Vicore Pharma Holding AB

By:

/s/ Ahmed Mousa

Ahmed Mousa

Chief Executive Officer

Date: November 5, 2026

3

View source ↗ · 中文页面